血管内皮生长因子家族在妇产科若干疾病中的研究进展

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (334 KB) HTML (25 KB)
输出: BibTeX | EndNote (RIS)

摘要血管内皮生长因子(VEGF)是一种高度特异性的促血管内皮细胞生长因子,在促进血管通透性增加、细胞外基质变性、血管内皮细胞迁移、增殖和血管形成等方面有着重要作用。同时,VEGF也可调节血管和淋巴管的生长,VEGF信号传导的失调与许多病理状态紧密相关,随着国内外研究人员对VEGF的深入研究,在妇产科领域包括肿瘤、复发性流产、子痫前期、胎儿生长受限(IUGR)等方面取得许多新的进展,本文就VEGF家族在妇产科几种常见疾病的新进展做一综述。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	杨舒奇
	黄明莉
	黄凌佳
	孙欣

关键词 ：血管内皮生长因子(VEGF), 肿瘤, 子痫前期, 复发性流产, 宫内生长受限(IUGR)

收稿日期: 2018-10-22

通讯作者: 黄明莉(doctor_hml@163.com)

引用本文:

杨舒奇, 黄明莉, 黄凌佳, 孙欣. 血管内皮生长因子家族在妇产科若干疾病中的研究进展[J]. 中国生育健康杂志, 2020, 31(2): 184-186.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2020/V31/I2/184

1 Gordon CJ,Robert K,Lee ME,et al.Antiangiogenic therapy in oncology:current status and future directions.Lancet,2016,388:518-529.
2 陈波,施秋秋,梁凯伦,等.孕康口服液调节复发性流产小鼠内分泌系统及VEGF 信号通路降低流产率的作用和机制.中国中药杂志,2018,43:1894-1900.
3 Karaman S,Leppnen VM,Alitalo K.Vascular endothelial growth factor signaling in development and disease.Development,2018,145:1-8.
4 MacGabhann F,Popel A.Dimerization of VEGF receptors and implications for signal transduction:a computational study.Biophys Chem,2007,128:125-139.
5 Hanahan D,Weinberg RA.Hallmarks of cancer:the next generation.Cell,2011,144:646-674.
6 Folkman J.Tumor angiogenesis:therapeutic implications.N Engl J Med 1971,285:1182-1186.
7 Jayson GC,Kerbel R,Ellis LM,et al.Antiangiogenic therapy in oncology:current status and future directions.Lancet,2016,388:518-529.
8 Minion LE,Tewari KS.Cervical cancer – State of the science:From angiogenesis blockade to checkpoint inhibition.Gynecol Oncol,2018,148:609-621.
9 Marquina G,Manzano A,Casado A.Targeted Agents in Cervical Cancer:Beyond Bevacizumab.Curr Oncol Re,2018,20:40.
10 Orbegoso C,Marquina G,George A,et al.The Role of Cediranib in Ovarian Cancer.Expert Opin Pharmacother,2017,18:1637-1648.
11 Khan KA,Kerbel RS.Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.Nat Rev Clin Oncol,2018,15:310-324.
12 Stirrat GM.Recurrent miscarriage.Lancet,1990,336:673-675.
13 Regan L.Recurrent miscarriage.BMJ,1991,302:543-544.
14 Torry DS,Hinrichs M,Torry RJ.Determinants of placental vascularity.Am J Reprod Immunol,2004,51:257-268.
15 Ferrara N,Gerber HP,LeCouter J.The biology of VEGF and its receptors.Nat Med,2003,9:669-676.
16 Hashemi M,Danesh H,Bizhani F,et al.The -2549 insertion/deletion polymorphism in the promoter region of VEGF is associated with the risk of recurrent spontaneous abortion.Biomed Rep,2018,8:297-300.
17 Bagheri A,Kumar P,Kamath A,et al.Association of angiogenic cytokines (VEGF-A and VEGF-C) and clinical characteristic in women with unexplained recurrent miscarriage.Bratisl Lek Listy,2017,118:258-264.
18 Sun Y,Chen M,Mao B,et al.Association between vascular endothelial growth factor polymorphism and recurrent pregnancy loss:A systematic review and meta-analysis.Eur J Obstet Gynecol Reprod Biol,2017,211:169-176.
19 Jung YW,Ahn EH,Kim JO,et al.Association of genetic polymorphisms in VEGF -460,-7 and -583 and hematocrit level with the development of idiopathic recurrent pregnancy loss and a meta-analysis.J Gene Med,2018,20:e3048.
20 Ferrara N,Adamis AP.Ten years of anti-vascular endothelial growth factor therapy.Nat Rev Drug Discov,2016,15:385-403.
21 Schuiling GA,Faas MM.Etiology and pathogenesis of preeclampsia:current concepts.Am J Obstet Gynecol,1999,181:1036-1037.
22 Robinson CJ,Stringer SE.The splice variants of vascular endothelial growth factor (VEGF) and their receptors.J CellSci,2001,114:853-865.
23 Zhou CC,Zhang Y,Irani RA,et al.Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice.Nat Med,2008,14:855-862.24 Eddy AC,Bidwell GL,George EM.Pro-angiogenic therapeutics for preeclampsia.Biol Sex Differ,2018,9:36.
25 Saleh L,Vergouwe Y,van den Meiracker AH,et al.Angiogenic Markers Predict Pregnancy Complications and Prolongation in Preeclampsia Continuous Versus Cutoff Values.Hypertension,2017,70:1025-1033.
26 Thadhani R,Hagmann H,Schaarschmidt W,et al.Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.J Am Soc Nephrol,2016,27:903-913.
27 Onda K,Tong S,Beard S,et al.Proton Pump Inhibitors Decrease Soluble fms-Like Tyrosine Kinase-1 and Soluble Endoglin Secretion,Decrease Hypertension,and Rescue Endothelial Dysfunction.Hypertension,2017,69:457-468.
28 Sharma D,Shastri S,Sharma P.Intrauterine growth restriction:antenatal and postnatal aspects.Clin Med Insights Pediatr,2016,10:67-83.
29 Lyall F,Robson SC,Bulmer JN.Spiral artery remodeling and trophoblast invasion in preeclampsia and fetal growth restriction relationship to clinical outcome.Hypertension,2013,62:1046-1054.
30 Vaughan OR,Rossi CA,Ginsbergn Y,et al.Perinatal and long-term effects of maternal uterine artery adenoviral VEGF-A165 gene therapy in the growth-restricted guinea pig fetus.Am J Physiol Regul Integr Comp Physiol,2018,315:R344-R353.
31 Sulistyowati S,Bachnas MA,Anggraini ND,et al.Recombinant vascular endothelial growth factor 121 injection for the prevention of fetal growth restriction in a preeclampsia mouse model.J Perinat Med,2017,45:245-251.
32 Takahashi N,Li F,Fushima T,et al.Vitamin B3 Nicotinamide:A Promising Candidate for Treating Preeclampsia and Improving Fetal Growth.Tohoku J Exp Med,2018,244:243-248.